(NewsDirect)
By Ernest Dela Aglanu, Benzinga
With the COVID pandemicstill ongoing, havingclaimed more than 6.8 million lives from about 758 millioncases and crippling the global economy, there are several reasons whydrug research and development related to the COVID virus remainshighly relevant and necessary.
Ongoing drug development by companies such as NanoViricides Inc. (NYSEAMERICAN: NNVC) is vital because newvariants of the virus keep emerging and viral infections,hospitalizations and deaths continue at a much greater rate than evenpandemic influenza years despite the roll-out of vaccines from playerslike Novavax Inc. (NASDAQ: NVAX), Moderna Inc. (NASDAQ:MRNA), Oxford– AstraZeneca plc (LON: AZN), and PfizerInc. (NYSE: PFE)–BioNTech
As newvirus variants continue to develop, researchers must stayahead of the curve to identify and combat them. Given thefast-evolving nature of the virus, early detection of these newvariants is thought to be crucial in controlling their spread andpreventing further outbreaks. However, with significantly reducedtesting worldwide, it is now widely understood that a new damagingvariant may not be readily identified before it spreads.
Even after 3 years ofpandemic, do we have effective drugs that could stop the next variant?Unfortunately, we don’t have even one safe and effective drug thatdoes not come with a lot of limitations. This is why the need to treatcurrent infections and also to better prepare for future pandemics hasspurred a new wave of investment andinterest in COVID research and development.
NanoViricides hasrecently reported that it is very close to testing its drug candidateNV-CoV-2 to treat SARS-CoV-2 infection in human clinical trials. Thusthe Company is nearing an inflection point in its lifecycle, with thefirst clinical trials of its unique and novel nanomedicines platform.
Human clinicaltrials are now becoming imminent — NanoViricides will no longer be aR&D/Drug Discovery company, but will soon become a clinical-stagepharma company. Traders and investors are taking note of what could bea unique opportunity.
NanoViricides, a growing innovator in nanomedicine andantiviral therapies, has been maturing its nanomedicine technology indeveloping drugs against many viruses for over 15 years, and theirmost recent developments could potentially prove to bemarket-disrupting with implications for treating dozens of virusesworldwide.
Allthese years of research and development are coming together forNanoViricides, now, positioning it to potentially become a majorplayer in the antivirals space.
NanoViricides has reported:
-
A platform technology that enables it todevelop drugs rapidly against many viruses as shown with manycandidates in pre-clinical studies against a number ofviruses.
-
Technology to make drugs that variants of the virus cannotescape because no matter how much the virus changes, it uses the samereceptor, and this company’s technology for first-in-class drugs isbased on making copies of that unique receptor.
-
A novelmechanism of action, enabling first-in-class drugs against viruses.
-
Technology to make broad-spectrum antiviral drugs. For example,the company has shown in preclinical studies that its COVID drug worksagainst all the tested coronaviruses.
-
The ability to manufacturefirst-in-class drugs at scale to make finished drug products forclinical trials of their lead candidate against COVID in its own cGMPcompliant manufacturing facility.
-
The COVID drug, NV-CoV-2, has beenformulated and tested in the form of Oral Gummies, and also as OralSyrup - to help COVID-positive patients, including children and olderpatients who need more accessible treatments.
Read the latestreport on NanoViricides here .
Dosing And EffectivenessNV-CoV-2 Reportedly Superior
An additional problem for current COVID cases isthat available COVID drugs like remdesivir by Gilead (NASDAQ:GILD), molnupiravir by Merck (NYSE: MRK), and to a lesserextent, Paxlovid by Pfizer (NYSE: PFE) face the challenge oflimited dosing for safety reasons — which is a part of why they havelimited effectiveness and limitations on use — increasing dosagewould not give increased benefit thus limiting the drugs’capability.
Unlike these drugs, the very high safety numbers that NV-CoV-2has demonstrated in rat studies indicate that patients might be ableto take more of the Company’s COVID drug to achieve greatereffectiveness when their sickness is more severe. This is expected tobe validated in imminent human clinical trials.
Once NanoViricidesproves that its COVID drug is safe in clinical trials, the company’sentire platform of nanotechnology would essentially be validated as being capable of developingsafe drugs.
Additionally, assuming NanoViricides demonstrates strongeffectiveness of the COVID drug in clinical trials, similar to thestrong effectiveness they have reported in their pre-clinical studies,that would validate the Company’s pre-clinical approach in studyingeffectiveness for developing clinical candidates, and will likely havestrong positive implications for the other drug candidates in theirpipeline too.
AsNanoViricides’ reported effective and safe solutions for battlingagainst the COVID pandemic move into the clinic, heralding itsofficial entry as a pharmaceutical drug maker, the story doesn’tstop there. Once the platform is proven, the Company could be wellpositioned to develop solutions to battle other current and futurepandemics as well. The company has drugs nearing clinical stage fortreating Shingles and Herpes Viruses (HSV-1 and HSV-2). And it says itwill be forging ahead to further develop candidates to battle HIV,Ebola/Marburg, Monkeypox, and other viruses.
With the globalantiviral therapy market valued at $48.1 billion in 2018 and estimated to garner $79.8 billion by2026, rising at a compound annual growth rate (CAGR) of 6.7% from 2019to 2026, NanoViricides could be strategically placed to participate insuch significant market size and growth while potentiallyrevolutionize the industry with the Company’s unique biomimetictechnology.
Headto https://profiles.smallcapsdaily.com/nnvc/ to read more aboutNanoViricides’ technology.
This article originally appeared on Benzinga here .
AboutNanoViricides
NanoViricides, Inc. (the "Company")(www.nanoviricides.com) is a development stage company that iscreating special purpose nanomaterials for antiviral therapy. TheCompany's novel nanoviricide® class of drug candidates aredesigned to specifically attack enveloped virus particles and todismantle them. Our lead drug candidate is NV-HHV-101 with its firstindication as dermal topical cream for the treatment of shingles rash.In addition, we are developing a clinical candidate for the treatmentof COVID-19 disease caused by SARS-CoV-2 coronavirus. The Companycannot project an exact date for filing an IND for this drug becauseof its dependence on a number of external collaborators andconsultants.The Company is now working on tasks for completing an INDapplication. The Company is currently pursuing two separate drugcandidates for the treatment of COVID-19 patients. NV-CoV-2 is ournanoviricide drug candidate that does not encapsulate Remdesivir.NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2with Remdesivir encapsulated in it. The Company believes that sinceRemdesivir is already US FDA approved, our drug candidateencapsulating Remdesivir is likely to be an approvable drug, if safetyis comparable. Remdesivir is developed by Gilead. The Company hasdeveloped both of its own drug candidates NV-CoV-2 and NV-CoV-2-Rindependently.The Company intends to re-engage into an IND applicationto the US FDA for NV-HHV-101 drug candidate for the treatment ofshingles once its COVID-19 project moves into clinical trials, basedon resources availability. The NV-HHV-101 program was slowed downbecause of the effects of recent COVID-19 restrictions, andre-prioritization for COVID-19 drug development work.The Company isalso developing drugs against a number of viral diseases includingoral and genital Herpes, viral diseases of the eye including EKC andherpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza,HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.NanoViricides' platform technology and programs are based on theTheraCour® nanomedicine technology of TheraCour, which TheraCourlicenses from AllExcel. NanoViricides holds a worldwide exclusiveperpetual license to this technology for several drugs with specifictargeting mechanisms in perpetuity for the treatment of the followinghuman viral diseases: Human Immunodeficiency Virus (HIV/AIDS),Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, HerpesSimplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV),Influenza and Asian Bird Flu Virus, Dengue viruses, JapaneseEncephalitis virus, West Nile Virus, Ebola/Marburg viruses, andcertain Coronaviruses. The Company intends to obtain a license forpoxviruses if the initial research is successful. The Company'stechnology is based on broad, exclusive, sub-licensable, fieldlicenses to drugs developed in these areas from TheraCour Pharma, Inc.The Company's business model is based on licensing technology fromTheraCour Pharma Inc. for specific application verticals of specificviruses, as established at its foundation in 2005.
This postcontains sponsored advertising content. This content is forinformational purposes only and not intended to be investingadvice.
Contact Details
NanoViricides,Inc.
+1 203-937-6137
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.